CurrentCentenePolicy CP.MP.62

Clinical Policy: Hyperhidrosis Treatments

Defines medical necessity criteria and coding guidance for treatments of primary hyperhidrosis (iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy) for members/enrollees of Centene-affiliated health plans.

Policy Summary

PayerCentene

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization and document trials of conservative management and required pharmacotherapy before requesting iontophoresis, axillary gland excision, or ETS.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3treatment types with criteria

9iontophoresis contraindications

7codes referenced

1miraDry mentioned

Medical Necessity Criteria

Iontophoresis (medically necessary)

Covered when ALL of the following are met

Iontophoresis criteria: Member has diagnosis of primary hyperhidrosis; development of medical complications (e.g., skin maceration with secondary skin infections) or significant constant disruption of professional and/or social life; unresponsive or unable to tolerate at least one pharmacotherapy for excessive sweating (e.g., anticholinergics, beta-blockers, benzodiazepines); failed a six-month trial of conservative management including adherent application of aluminum chloride hexahydrate (prescription Drysol) or topical agents caused severe rash; no contraindications (cardiac pacemaker, cardiac arrhythmias, pregnancy, relevant metal implants depending on size/position, cracked skin near treatment area)

Surgical excision of axillary sweat glands (medically necessary)

Covered when ALL of the following are met

Axillary gland excision criteria: Meets all of the iontophoresis criteria I.A–I.D; has persistent and severe primary hyperhidrosis; has failed one of the following: iontophoresis or trial of botulinum toxin

Policy Summary

PayerCentene

PolicyClinical Policy: Hyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization and document trials of conservative management and required pharmacotherapy before requesting iontophoresis, axillary gland excision, or ETS.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis (medically necessary)

Covered when ALL of the following are met

ETS criteria: Meets all of the iontophoresis criteria I.A–I.D; resting heart rate > 55 beats per minute; hyperhidrosis symptoms began at an early age (usually < 16 years) and surgery is requested for a young member (usually < 25 years); body mass index < 28; reports no sweating during sleep; no significant comorbidities; has persistent and severe primary hyperhidrosis; has failed one of the following: iontophoresis or trial of botulinum toxin for predominantly axillary hyperhidrosis; member has been counseled on risks of the procedure

Procedure and Clinical Coding Guidance

Referenced CPT/Modality Codes (informational)CPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877	Suction assisted lipectomy; trunk.
15878	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes.

inv-08: Resting heart rate — > 55 beats per minute

Resting heart rate thresholdGreater than 55 beats per minute

Where appliedRequirement for endoscopic thoracic sympathectomy (ETS) medical necessity

Document source languagePolicy states: 'Has a resting heart rate > 55 beats per minute'

inv-09: Age of symptom onset — < 16 years (for ETS criteria)

Age of symptom onsetUsually less than 16 years

ContextUsed as part of ETS medical necessity criteria (symptoms started at an early age)

Related requirementSurgery often requested for young members (usually < 25 years) as noted in policy

inv-10: Age for surgery request — < 25 years (young member/enrollee)

Age for surgery requestUsually less than 25 years of age

ContextReferenced alongside early symptom onset in ETS medical necessity criteria

Policy phrasing'surgery is requested for a young member/enrollee (usually < 25 years of age)'

inv-11: Body mass index — < 28

Body mass index thresholdBody mass index (BMI) less than 28

ApplicationRequirement within ETS medical necessity criteria

Policy citationPolicy states: 'Body mass index < 28'

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required for procedures when seeking coverage for iontophoresis, surgical excision of axillary sweat glands, or endoscopic thoracic sympathectomy (ETS). Submit a request to the plan prior to scheduling the procedure to ensure benefits determination and medical necessity review.

Affected services: iontophoresis, excision of axillary sweat glands, ETS
Include anticipated CPT codes on request (see coding section)

Step Therapy

Step Therapy Requirements

A stepwise approach is required prior to authorization of procedural interventions. Members must have attempted and documented conservative measures and at least one pharmacotherapy trial before procedures will be considered.

Conservative management: adherent application of aluminum chloride hexahydrate (e.g., prescription Drysol) for a trial of at least 6 months
Pharmacotherapy: trial of at least one systemic agent (e.g., anticholinergics, beta-blockers, or benzodiazepines) unless contraindicated or not tolerated
Procedural prerequisites: failure of iontophoresis and/or trial of botulinum toxin is required for surgical excision or ETS per policy

Documentation Required

Required Documentation

Document and submit clinical information demonstrating medical necessity. Complete documentation reduces delays and supports approval.

Diagnosis of primary hyperhidrosis (site specified: palmar, axillary, plantar, etc.)
Severity and impact: description of functional impairment or significant disruption to professional/social life (e.g., recurrent changing of clothes, occupational impact)
Medical complications, if present (e.g., skin maceration, recurrent secondary skin infections)
Prior therapies and responses: dates and outcomes of conservative management (including 6-month trial of aluminum chloride hexahydrate), pharmacotherapy trials (medication names, doses, duration, intolerance or adverse reactions), iontophoresis and/or botulinum toxin trials and outcomes
Contraindications assessment: presence/absence of cardiac pacemaker, cardiac arrhythmias, pregnancy status, metal implants near treatment area, cracked skin at treatment site
For ETS: resting heart rate, age at symptom onset, current age, body mass index, report of no sweating during sleep, counseling on surgical risks, and absence of significant comorbidities

Denial Risk

Potential Triggers for Denial

Claims or authorization requests may be denied if required step therapy or documentation is incomplete or missing. Providers should verify that all prerequisites and supporting records are included.

Potential triggers for denial include: lack of documented 6-month trial of conservative management with aluminum chloride hexahydrate; no documentation of a trial or intolerance to at least one pharmacotherapy; absence of documented trial/failure of iontophoresis or botulinum toxin when required for surgical procedures; missing documentation of severity/functional impact or medical complications; presence of documented contraindications (e.g., pacemaker) without rationale for proceeding; incomplete clinical data for ETS (heart rate, BMI, age criteria, counseling)

Key Definitions

inv-17: Primary hyperhidrosis — definition and common sites

DefinitionVisible, excessive focal sweating of at least six months' duration without apparent cause (idiopathic)

Common sitesAxillae (underarms), palms (hands), and soles (feet)

Pathophysiology noteInduced by sympathetic hyperactivity in selected areas and not associated with underlying disease process

inv-18: Secondary hyperhidrosis — generalized or craniofacial sweating due to medications or underlying disease

DefinitionExcessive sweating that is generalized or craniofacial and caused by medications or underlying disease

Common causes (examples)Medications (e.g., tricyclic antidepressants, SSRIs) and underlying conditions (e.g., febrile illnesses, diabetes mellitus, menopause)

PatternUsually presents as generalized or craniofacial sweating; may include gustatory hyperhidrosis related to nerve injury or surgery

OpenPayer

Clinical Policy: Hyperhidrosis Treatments

Medical Necessity Criteria

Procedure and Clinical Coding Guidance

Prior Authorization, Documentation, and Step Therapy

Clinical Background

Key Definitions